| Project Detail |
A bone marrow biomimetic system for ex vivo platelet production
Platelet transfusion is a life-saving procedure used in clinical practice to prevent or stop bleeding in patients suffering from low platelet count. Current demands have increased due to the ageing population and harsh anti-cancer therapies, but the supply of blood donors falls short. Funded by the European Innovation Council, the SilkPlatelet project is introducing a new technology for the ex vivo production of platelets. The system comprises a bioreactor that mimics the bone marrow niche and allows the differentiation of haematopoietic stem cells into megakaryocyte precursors. Importantly, it complies with good manufacturing practice guidelines and is suitable for patients that have demonstrated immune reaction to previous transfusions.
The generation of ex vivo functional megakaryocytes (MK) and platelets is questioning current transfusion medicine exclusive reliance on blood donors to produce platelets. The demand for platelets is, in fact, in continuous rise, driven by an aging population, advances in medical procedures and even more aggressive cancer therapies, although the supply of blood donors continues to remain stagnant. Ex vivo platelet production systems have then emerged as a feasible supply that can moreover secure universal compatibility to avoid platelet refractoriness. If during the FET Open application we have proved that the platelet production ex vivo can be precision-tailored with the correct physical and biochemical environment, now with SilkPlatelet our consortium is looking forward to demonstrating the feasibility of an upscaled ex vivo production system. To bring then our technology from TRL4 to TRL6 we will increase the ex vivo platelet production capacity with media and stem cells aligned to GMP requirements for large-scale clinical transfusion. Our goal is to produce universal platelets particularly for patients with immune reaction to previous transfusions with HLA null platelets and patients with acute hemorrhage. At the core of our ?from lab-to-patients? roadmap, we will find both UNICAM proprietary technology to differentiate stem cells into MK precursors (natural source of platelets) and UNIPV disruptive bioreactor made of a silk-scaffold to mimic the bone marrow conditions. These will be then complemented by IGR long-term experience in iPSC and MK biology, and ISENET cell quality control contribute to the standardization of the platelet production pipeline and its validation and verification. Under the guidance of our experienced tech transfer officers, by the end of the project we expect to complete the transition into a commercial innovation exploited by a next university spin-out. |
